Brief: Abvc Biopharma Provides Abv-1601 Update On Phase I Site Initiation Visit Conducted At Cedars-Sinai Medical Center
April 10 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES ABV-1601 UPDATE ON PHASE I SITE
INITIATION VISIT CONDUCTED AT CEDARS-SINAI MEDICAL CENTER (CSMC)
* ABVC BIOPHARMA - EXPECTS TO INITIATE PHASE II STUDY OF
ABV-1601
IN Q4 OF 2023 AND THEN COMPARE RESULTS TO WELLBUTRIN XL
Source text for Eikon: ID:nGNX3ndsVj
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon